Work

Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.5034

Authors: Eric Jay Small, Fred Saad, Dana E. Rathkopf, Boris A. Hadaschik, Simon Chowdhury, Margaret K. Yu, Angela Lopez-Gitlitz, Oliver Brendan Rooney, Youyi Shu, Mohamed Darif, Matthew Raymond Smith

Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Centre Hospitalier de l’Université de Montréal, Université de Montréal, Memorial Sloan Kettering Cancer Center, University of Duisburg-Essen, St Thomas' Hospital, Janssen (United Kingdom), Harvard University, Massachusetts General Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2889634640

Cites:

Cited by: 4

Related to: 10